Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant

Harvard Apparatus Regenerative Technology, Inc.

Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.
Initial annual base salary of $250,000, plus $25,000 bonus for remainder of FY2022 subject to milestones.
Granted nonqualified stock option for 116,156 shares vesting equally over four years.
Company intends to relist on NASDAQ and start clinical trial for esophageal implant.
Interim CEO David Green highlights Damasio's skills for operational management and capital raises.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph L. Damasio, Jr.

Chief Financial Officer

HRGN · Harvard Apparatus Regenerative Technology, Inc.

Effective: 2022-08-08
Filed: August 10, 2022, 7:59 PM ET

Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph L. Damasio, Jr. was appointed as Chief Financial Officer at Harvard Apparatus Regenerative Technology, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.

View on SEC.gov

Harvard Apparatus Regenerative Technology, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-088054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.